The capital is pricing Novo Nordisk's oral semaglutide as a primary-care metabolic platform; the Phase 3 OASIS 1 trial, 667 patients, primary endpoint met on body-weight reduction but the cardiovascular outcome data from SOUL -- 9,650 patients, median follow-up 49.5 months -- showed a hazard ratio for MACE of 0.86 (95% CI 0.77-0.96), a result MOH Singapore's Pharmaceutical Division is reading as supportive of label expansion but not sufficient for the cardiometabolic indication Novo's APAC pricing model requires. The capital is pricing a unified metabolic franchise. The trial is delivering a weight endpoint with a cardiovascular signal that is statistically significant but smaller than the one that unlocked semaglutide's injectable formulation in SUSTAIN-6 (HR 0.74, 0.58-0.95, 3,297 patients).

The NMPA's Center for Drug Evaluation accepted Novo's oral semaglutide dossier for expedited review in March 2026, a queue that runs 12-to-18 months under standard CDE procedure; that clock and the capital's pricing of a 2027 mainland launch are running on the same assumption, which is that the CDE will not require a bridging pharmacokinetic study in a Han Chinese population despite documented absorption variability with the SNAC co-formulation at the 14 mg dose. A Guangzhou Phase 2 site enrolled 112 patients in a PK sub-study that has not yet reported -- the SOUL data will not resolve that gap, and neither will the family-office positions that allocated to Novo's APAC growth thesis in Q1 2026 before the sub-study readout is scheduled, currently flagged for Q4 2026 on ClinicalTrials.gov identifier NCT06184971.